The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma

Habbous, Steven; Guo, Helen; Beca, Jaclyn; Dai, Wei; Isaranuwatchai, Wanrudee; Cheung, Matthew C.; Chan, Kelvin K.

doi:10.1002/cam4.3362

Cited by 4 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides, we also found that HIV-associated features, which include CD4 cell count did not affect prognosis of HIV-associated BL. Habbous et al [21] also found that HIV status did not affect prognosis for patients with DLBCL receiving R-CHOP in a general population.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

HIV‐associated Burkitt lymphoma in the combination antiretroviral therapy era: Real‐world outcomes and prognostication

Wang

Liang

Quan

et al. 2022

eJHaem

View full text Add to dashboard Cite

We performed a retrospectively study to analyze the clinical characteristics and outcomes of HIVassociated Burkitt's lymphoma in Chongqing University Cancer Hospital (CUCH), southwest China, from March 2012 to February 2022. In the entire cohort, the median age was 36 years (range, 28-60 years), and more patients were male (82.4%). The median CD4 + T cell count was 214/μl (range, 54-601), of whom 47.1% had a CD4 + T cell count below 200/μl. Most patients had elevated LDH, elevated β 2 -MG, extranodal involvement and advanced Ann Arbor stage at diagnosis. With a median follow-up of 11.5 months (range, 1.6-94.9 months), the overall 1-year PFS and OS rates were 27.6% and 47.6% respectively.The 1-year OS times in the LDH<3 upper limit of normal and LDH≥3 upper limit of normal groups were 62.5% and 31.3%, respectively (p=0.008). The 1-year OS times in the received <4 cycles and ≥4 cycles groups were 0 and 77.8%, respectively (p<0.001). These results demonstrated that LDH<3 upper limit of normal and received ≥4 cycles chemotherapy were signi cantly associated with improved outcomes. However, rituximab administration was not signi cantly associated with improved outcomes.

show abstract

Section: Discussionmentioning

confidence: 92%

“…Habbous et al. [ 21 ] also found that HIV status did not affect prognosis for patients with DLBCL receiving R‐CHOP in a general population.…”

Section: Discussionmentioning

confidence: 99%

HIV‐associated Burkitt lymphoma in the combination antiretroviral therapy era: Real‐world outcomes and prognostication

Wang

Liang

Quan

et al. 2022

eJHaem

View full text Add to dashboard Cite

show abstract

“…In this retrospective study, we investigated predictors of survival for HIV-associated B-cell lymphoma. Whether HIV status impairs outcomes of DLBCL patients treated with standard immunochemotherapy in the HAART era remains controversial, 23 - 25 which means that prognostic factors might differ between these 2 groups. By RNA-seq, Fedoriw et al 26 identified a strong contribution of HIV status to DLBCL gene expression.…”

Section: Discussionmentioning

confidence: 99%

Identifying Factors Affecting the Survival of Patients with HIV-Associated B-Cell Lymphoma Using a Random Survival Forest Model

Zhao,

Zhu,

Lian

et al. 2024

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: There have been no reports about the application of random survival forest (RSF) model to predict disease progression of HIV-associated B-cell lymphoma. Methods: A total of 44 patients with HIV-associated B-cell lymphoma who were referred to Nanjing Second Hospital from 2012 to 2019 were included. The RSF model was used to find predictors of survival, and the results of the RSF model were compared with those of the Cox model. The data were analyzed using R software (version 4.1.1). Results: One-, 2-, and 3-year survival rates were 74.5%, 57.7%, and 48.6%, respectively, and the median survival was 59.0 months. The first 3 most important predictors of survival included lactate dehydrogenase (LDH), absolute monocyte count (AMC), and white blood cells (WBCs) count. The median survival of high-risk patients was only 4.0 months. Areas under the curve (AUCs) of the RSF model remained at more than 0.90 at 1, 2, and 3 years. The RSF model displayed a lower prediction error rate (21.9%) than the Cox model (25.4%). Conclusions: Lactate dehydrogenase, AMC, and WBCs count are the most important prognostic predictors for patients with HIV-associated B-cell lymphoma. Much larger prospective and/or multicentre studies are required to validtae this RSF model.

show abstract

“…Основная характеристика ПВЛ -опухолевые выпоты в полостях тела без обнаруживаемых опухолевых масс. Для данных нозологических лимфом Национальная всеобщая онкологическая сеть (NCCN, США) рекомендует общий терапевтический подход (R-EPOCH, R-CHOP) с профилактикой поражения ЦНС метотрексатом и цитарабином с активным наблюдением на момент развития инфекционных осложнений [20,[22][23][24][25][26].…”

Section: первичная выпотная лимфомаunclassified

HIV-associated lymphomas

Дудина

Mabudzada

Ogannisyan

et al. 2023

Kreativnaâ hirurgiâ i onkologiâ

View full text Add to dashboard Cite

A steady worldwide increase in the number of people living with HIV (PLHIV) and diagnostic methods requires a separate review of patient-specific nosologies, including lymphoproliferative diseases, some of which are directly associated with the virus due to its oncogenic effect and those that do not relate directly to HIV but introduce nuances to diagnostic and therapeutic approaches when a patient is HIV-positive. Towards this, the paper generally reviews lymphomas in PLHIV, presents the WHO classification of HIV-associated lymphomas, describes a contemporary view of the known mechanisms of pathogenesis, including the role of opportunistic infections, and general principles of diagnostic and therapeutic tactics, provides recommendations on modifying the doses of chemotherapy correlated with the immune status and on preventing CNS involvement. Specific types of lymphoma (Burkitt’s lymphoma, diff use large B-cell lymphoma) are considered separately, including those most frequently associated with patients living with HIV (primary effusion lymphoma, plasmablastic lymphoma, primary central nervous system lymphoma), but rare in the uninfected population.

show abstract

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 4 publications

References 34 publications

HIV‐associated Burkitt lymphoma in the combination antiretroviral therapy era: Real‐world outcomes and prognostication

HIV‐associated Burkitt lymphoma in the combination antiretroviral therapy era: Real‐world outcomes and prognostication

Identifying Factors Affecting the Survival of Patients with HIV-Associated B-Cell Lymphoma Using a Random Survival Forest Model

HIV-associated lymphomas

Contact Info

Product

Resources

About